# US 2014/0194391 A1 · Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194391 A1
- Document ID: US20140194391A1
- Status: Published application
- Kind: A1
- Application number: 14/075,878
- Filed: 2013-11-08
- Published: 2014-07-10
- Earliest claimed: 2004-07-06
- Assignees: Universite De Strasbourg; NormOxys, Inc.
- Applicants: Universite de Strasbourg; NormOxys, Inc.
- Inventors: Yves Claude Nicolau; Jean-Marie Lehn; Konstantina C. Fylaktakidou; Ruth Greferath
- Web page: https://patentgrep.com/patent/US20140194391A1

## CPC

- A61K 31/6615: Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A61K 31/66: Phosphorus compounds
- A61P 35/04: specific for metastasis
- C07F 9/093: {Polyol derivatives esterified at least twice by phosphoric acid groups}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a mixture of a sodium and a calcium salt of inositol tripyrophosphate (ITPP) and a pharmaceutically acceptable adjuvant, diluent, carrier, or excipient thereof.

### Claim 19

A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a mixture of a sodium and a calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate and a pharmaceutically acceptable adjuvant, diluent, carrier, or excipient thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is selected from one or more of breast cancer, prostate cancer, renal cell cancer, brain cancer, ovarian cancer, colon cancer, bladder cancer, pancreatic cancer, stomach cancer, esophageal cancer, cutaneous melanoma, liver cancer, lung cancer, testicular cancer, kidney cancer, bladder cancer, cervical cancer, lymphoma, parathyroid cancer, penile cancer, rectal cancer, small intestine cancer, thyroid cancer, uterine cancer, Hodgkin's lymphoma, lip and oral cancer, skin cancer, leukemia, and multiple myeloma.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is selected from one or more of breast cancer, prostate cancer, renal cell cancer, brain cancer, ovarian cancer, colon cancer, bladder cancer, pancreatic cancer, stomach cancer, esophageal cancer, cutaneous melanoma, liver cancer, lung cancer, testicular cancer, kidney cancer, bladder cancer, cervical cancer, lymphoma, parathyroid cancer, penile cancer, rectal cancer, small intestine cancer, thyroid cancer, uterine cancer, Hodgkin's lymphoma, lip and oral cancer, skin cancer, leukemia, and multiple myeloma.

### Claim 22 (depends on 19)

The method of claim 19, wherein the dosage of myo-inositol 1,6:2,3:4,5 tripyrophosphate is about 0.5 to about 1.5 g/kg.

### Claim 23 (depends on 22)

The method of claim 22, wherein the composition is formulated for intravenous administration.